SCHEMBL21872971

SCHEMBL21872971

Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1C=O

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 5/20 0.53
▸ PDGFRB P09619 3/20 0.53
▸ PDGFRA P16234 3/20 0.53
▸ LCK P06239 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ PTK6 Q13882 1/20 0.53
▸ KDR P35968 1/20 0.35
▸ FGFR1 P11362 1/20 0.34
▸ SYK P43405 11/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ PDE4B Q07343 2/20 0.32
▸ PDE7A Q13946 2/20 0.32
▸ PDE7B Q9NP56 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25317059 0.78 PDGFRB (0.47) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25911644 0.77 CSF1R (0.47) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL31741098 0.76 CSF1R (0.82) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25912094 0.76 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25911603 0.75 CSF1R (0.48) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21873156 0.75 CSF1R (0.52) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25911557 0.74 PDGFRB (0.42) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25319475 0.74 CSF1R (0.47) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL25911369 0.73 CSF1R (0.45) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL31740962 0.73 CSF1R (0.70) CSF1RPDGFRBPDGFRALCKKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback